Review of Vaccinia Virus for Lung Cancer Therapy and Systemic Immunotherapy

A 200 KB review document authored by Linkai Li, published on figshare under CC-BY-4.0 license and last updated on May 7, 2026. The text discusses the preclinical progress of vaccinia virus as an oncolytic and immunotherapeutic agent for lung cancer, particularly in non-small cell lung cancer models.

Use Cases

• Reviewing preclinical evidence for vaccinia virus efficacy in lung cancer models based on the described review content.
• Analyzing engineering strategies for converting 'cold' tumors based on the discussion of cytokine expression and enhanced costimulation.
• Evaluating obstacles for systemic delivery of viral therapies based on the discussion of inefficient systemic delivery and immunosuppressive feedback.
• Identifying rational combination strategies with checkpoint inhibitors based on the review's discussion of therapeutic combinations.

Strengths

• The document is a focused review on a specific therapeutic approach (vaccinia virus for lung cancer).
• It is published under an open CC-BY-4.0 license.
• The author (Linkai Li) is identified, providing attribution.

Limitations

• The dataset is a single 200 KB DOCX file, indicating a limited scope of textual content rather than a large data collection.
• Column-level documentation is absent; the content structure must be inferred from the document itself.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.

Provenance

Source

figshare

Collection Method

Likely authored as a review article.

Freshness

Last updated 2026-05-07 04:44:01; freshness should be verified.